Equities Analysts Offer Predictions for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at Wedbush reduced their Q1 2025 earnings per share estimates for shares of Biogen in a report issued on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $3.51 per share for the quarter, down from their previous estimate of $3.82. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $17.02 EPS and FY2027 earnings at $17.83 EPS.

BIIB has been the subject of a number of other reports. Bank Of America (Bofa) decreased their price objective on Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a report on Tuesday, February 11th. Citigroup decreased their price target on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Truist Financial cut their price objective on shares of Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down previously from $138.00) on shares of Biogen in a research report on Tuesday, February 18th. Finally, BMO Capital Markets lowered their price target on shares of Biogen from $156.00 to $139.00 and set a “market perform” rating on the stock in a research note on Thursday, February 13th. Eighteen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $213.15.

Biogen Price Performance

BIIB stock opened at $115.29 on Thursday. The stock has a 50-day moving average price of $135.18 and a two-hundred day moving average price of $152.70. Biogen has a 1 year low of $110.04 and a 1 year high of $238.00. The stock has a market cap of $16.88 billion, a PE ratio of 10.30, a price-to-earnings-growth ratio of 1.51 and a beta of 0.06. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

Institutional Trading of Biogen

Institutional investors have recently bought and sold shares of the business. Missouri Trust & Investment Co increased its holdings in shares of Biogen by 63.6% during the first quarter. Missouri Trust & Investment Co now owns 6,325 shares of the biotechnology company’s stock worth $866,000 after purchasing an additional 2,460 shares during the period. Opal Wealth Advisors LLC bought a new position in Biogen during the 1st quarter worth $26,000. Wealth Enhancement Advisory Services LLC raised its holdings in Biogen by 15.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 19,049 shares of the biotechnology company’s stock valued at $2,607,000 after acquiring an additional 2,606 shares in the last quarter. CVA Family Office LLC lifted its position in shares of Biogen by 71.1% during the 1st quarter. CVA Family Office LLC now owns 231 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 96 shares during the period. Finally, NorthCrest Asset Manangement LLC grew its holdings in shares of Biogen by 6.6% during the 1st quarter. NorthCrest Asset Manangement LLC now owns 34,532 shares of the biotechnology company’s stock worth $4,725,000 after purchasing an additional 2,126 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Insider Buying and Selling

In related news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.